Anika Therapeutics, Inc. (ANIK) Tops Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.72 --0%
EPS Growth %: +115.4%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +115.4%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.40, $0.07 better than the analyst estimate of $0.33. Revenue for the quarter came in at $22.1 million versus the consensus estimate of $20.33 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Sharon AI surges premarket; New Oriental gains, Medline slips
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
